Dr. Kavitha Saravu - Principal Investigator for a post marketing survey of premix insulin analogue (Novomix) to the existing therapy. (START survey), Oct 2010-Jan 2011.

Double blind, phase III Randomized study to evaluate the safety and efficacy of BAL88557 Versus Caspofungin followed by Voriconazole Regimen in the treatment of candidemia and other invasive candida infection funded by Quintiles.

Randomized open label 12 week comparative study the efficacy of Trigline in patient with hyperglyceridemia funded by apex laboratories.

Randomized multicenteric double-blind phase 3 trial to evaluate the efficacy and safety of saxagleptin (BMs477118) as Monobherapy with titration in subject with type 2 diabetes who have inadequate glycemic control with diet and exercise funded by Icon.

Mulcenteric, Randomized, Double blind, study to Determine the efficacy and safety of the addition of SYR- 322 25mg versus Dose titration from 30mg to 45mg of ACTos Pioglitazole HCI I subject with Type 2 diabetes mellitus who have inadequate control on a combination of Metformin and 30mg of Pioglitazone HCI therapy funded by PPDI.

Randomised multicentric, Double blind placebo controlled study to determine the efficacy and safety of combination of (SYR-322) in subject with Type 2 diabetes. Funded by PPDI.

Randomised double blind, placebo controlled, parallel, multicenter study of the safety and efficacy and efficacy of two dosages of Bicifadine SR in adult outpatient with chronic neuropathic pain associated with Diabetic peripheral neuropathy. Funded by GVK biosciences.

Long term, open label extension study to investigate the long term safety of SYR 110322(SYR-322) in subject with type 2 diabetes.

Dr. Kavitha Saravu -Principle investigator for Efficacy and tolerability of RIVOLIX064019 in patients with type 2 diabetes mellitus. Phase IV study –An open label, multicentric non comparative post marketing surveillance study.(Ranbaxy labs)- 2007. Dr Mahesh Docherla and Dr. Shastry were co-investigators

Dr Kavitha Saravu, Shastry BA. Phase III study Efficacy and tolerability of …. fibrate and Losartan in patients with hypertension and hyperuricemia & Dyslipidemia, Sponsor :Ranbaxy Labs)

Dr Sudha Vidyasagar, Varma M, Prashanth CK, Pankaj Seth. A multicenter, Randomised, Double-blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of the study drug as Monotherapy with titration in subjects with Type 2 Diabetes who have Inadequate Glycemic Control with Diet and Exercise – (CRO –ICON and SPONSOR – BMS)

A Phase 2/3, Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-group, Multicenter Study to determine the Safety and Efficacy of the study drug in the treatment of Type 2 Diabetes in Patients suboptimally controlled on Insulin.- (CRO –ICON and SPONSOR – METABOLEX)

A randomized, double-blind, placebo and active comparator-controlled, parallel-group study for the efficacy and safety of study drug as Monotherapy treatment of type 2 diabetes mellitus. (CRO – ICON and SPONSOR – DAIICHI SANKYO)

A phase 2, open-label, non-comparative study of study drug in the treatment of nosocomial and Ventilator-associated pneumonia in hospitals where Pseudomonas aeruginosa may be a prevalent pathogen. (CRO – Quintiles and SPONSOR- JASSEN-NEIL)

An Open-label 52 week Safty Study of study drug in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy (CRO- GVK Bioscience and SPONSOR – XTL Inc.Research)

A Double-Blind, Randomized, Placebo- controlled, Parallel, Multicenter Study of the Safety and Efficacy of Two Dosages of study drug in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy(CRO- GVK Bioscience and SPONSOR – XTL Inc. Research

Self reported health problems in mobile phone usersInvestigator – Dr Rohith Valsalan Dr. Maneesh Mailankot, Rachana

Principle investigator: “Randomized multicentric clinical on Epratazumab in serologically active SLE” Dr Mukhyaprana Pabhu

Principal Investigator for a post marketing survey of premix insulin analogue (Novomix)to the existing therapy. (START survey), Oct 2010-Jan 2011

Dr. Kavitha Saravu-Principal Investigator for a randomized double blind multicentric study to determine the efficacy and safety of Albuglutide with Sitagliptine in subjects with type 2 diabetes mellitus with renal impairment. GLP 114130. GSK Sept 2010.

Dr. Kavitha Saravu-Principal Investigator for a randomized. Open label, multicentric study to determine the efficacy and safety of Albuglutide as compared with Liraglutide in subjects with type 2 Diabetes Mellitus. GLP 114179. GSK Sept 2010.

Dr. Kavitha Saravu-Principal investigator for 12 week, phase II, randomized double blinded, placebo controlled, dose ranging, parallel group study to evaluate the safety, tolerability and efficacy of once daily PF-04971729 and Sitagliptine on glycemic control and body weight in adult patients with type 2 diabetes mellitus inadequately controlled on metformin. -2010 -Pfizer

Dr. Kavitha Saravu-Principal investigator for a phase III, randomized, open label, Active controlled, Parallel group, multicentre study to determine the safety and efficacy of Albiglutide administered in combination with Insulin Glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes mellitus. 2010 –Pfizer

Dr. Kavitha Saravu-Principal investigator for a multicenter, open label, nonrandomized, non interventional, observational, safety and efficacy study in hospitalized subjects using Novorapid - A Post Marketing study (Phase IV) of Novorapid -2008 -2009.(Novo Nordisk)

Dr. Kavitha Saravu-Principal investigator for Efficacy and tolerability of VOLIX (Voglibose) in patients with type 2 diabetes mellitus. Study code RIVOLIX064019; Phase IV study –An open label, multicentric non comparative post marketing surveillance study. (Ranbaxy labs)- 2007. ***

Dr. Kavitha Saravu-Principal investigator for Post marketing surveillance study on Atorvastatin – Modlip (Atorvastatin – Torrent Pharma) conducted between November 2005 to April 2006.